Moderna Inc. today announced that its mRNA-1273 vaccine candidate against COVID-19 is 94.5% effective, according to early data.

The candidate is currently subject to a phase 3 clinical trial, with 30,000 U.S. participants enrolled, including those at high risk of severe COVID-19 complications.

The Moderna announcement follows similar claims of effectiveness by a vaccine candidate developed by Pfizer and BioNTech, with a prominent difference between the two vaccines; while the Pfizer candidate must be stored at minus 80 degrees Celsius, Moderna’s is stable between 2 and 8 degrees Celsius — the temperature of standard refrigerators — for up to 30 days.

Moderna expects to produce approximately 20 million doses of its vaccine by the end of 2020, with an additional 500 million to 1 billion doses worldwide in 2021. Of this stock, the U.S. has already purchased 100 million doses, pending Food and Drug Administration approval.

Related News Articles

Headline
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Fusce congue lorem nisl, ac dapibus dui vestibulum ut. Vivamus egestas at ipsum eget posuere.…
Headline
As of Nov. 6, about 60% of the nation’s retail pharmacies have agreed to participate in a federal program to administer COVID-19 vaccines at no cost to…
Perspective
“Don’t let perfect be the enemy of the good” is a quote credited to the French writer and thinker Voltaire. Although he died in 1778, that phrase is very…
Headline
To continue amplifying the important message of protecting against both the flu and COVID-19, AHA’s Wear A Mask and United Against the Flu campaigns today…
Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response has released guidance on considerations for health…
Headline
The Department of Health and Human Services will host an additional webinar Nov. 13 at 1 p.m. ET on the Centers for Medicare & Medicaid Services’ Oct. 6…